Momeallerg (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, altering gene transcription to suppress the production of inflammatory mediators such as cytokines and prostaglandins. This reduces vascular permeability, edema, and immune‑cell infiltration, providing anti‑inflammatory relief.

The prescribed dose of Momeallerg is determined by the treating clinician based on the patient’s condition and response. Typical regimens involve one spray per nostril once daily, but the exact amount and frequency should follow the prescriber’s instructions.

Safety data for mometasone furoate nasal spray during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Momeallerg.

To request Momeallerg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Momeallerg (mometasone furoate) is a high‑potency corticosteroid with minimal systemic absorption, similar to fluticasone propionate. Clinical studies suggest comparable efficacy in reducing nasal symptoms, while the dosing frequency is often once daily, which may improve adherence compared with some alternatives that require twice‑daily dosing.

Momeallerg should be stored at room temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and potency throughout its shelf life.

Momeallerg is administered as a nasal spray. The patient tilts the head slightly forward, inserts the nozzle into one nostril, and gently presses the actuator while breathing in through the nose. The same procedure is repeated in the other nostril if prescribed.

Serious risks, though rare, include nasal septal perforation, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal passages. Patients should report persistent nosebleeds, visual changes, or signs of systemic glucocorticoid excess to their clinician promptly.

Momeallerg should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections or recent nasal surgery unless cleared by a healthcare professional.